Brief: Travere Therapeutics And CSL Vifor Announce Swissmedic Approval Of FILSPARI For Treatment Of IgA Nephropathy
17/10/2024 12:34
Oct 17 (Reuters) - CSL Ltd CSL.AX :
* TRAVERE THERAPEUTICS AND CSL VIFOR ANNOUNCE SWISSMEDIC
APPROVAL
OF FILSPARI® (SPARSENTAN) FOR THE TREATMENT OF IGA NEPHROPATHY
Source text for Eikon: ID:nGNX551XBJ
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule